Defining a correlate of protection for chikungunya virus vaccines

Gregg Milligan, Barbara S. Schnierle, Alexander J. McAuley, David Beasley

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Chikungunya virus
Vaccines
Clinical Trials
vaccines
complications (disease)
Licensure
endpoints
fever
Disease Outbreaks
clinical trials
Fever
planning
infection
testing

Keywords

  • Animal models
  • Arbovirus
  • Assays
  • Clinical trial
  • Neutralizing antibodies
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Defining a correlate of protection for chikungunya virus vaccines. / Milligan, Gregg; Schnierle, Barbara S.; McAuley, Alexander J.; Beasley, David.

In: Vaccine, 01.01.2018.

Research output: Contribution to journalArticle

@article{031ab05877054f2188986268853aded5,
title = "Defining a correlate of protection for chikungunya virus vaccines",
abstract = "Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.",
keywords = "Animal models, Arbovirus, Assays, Clinical trial, Neutralizing antibodies, Vaccine",
author = "Gregg Milligan and Schnierle, {Barbara S.} and McAuley, {Alexander J.} and David Beasley",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2018.10.033",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Defining a correlate of protection for chikungunya virus vaccines

AU - Milligan, Gregg

AU - Schnierle, Barbara S.

AU - McAuley, Alexander J.

AU - Beasley, David

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.

AB - Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.

KW - Animal models

KW - Arbovirus

KW - Assays

KW - Clinical trial

KW - Neutralizing antibodies

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85056621126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056621126&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.10.033

DO - 10.1016/j.vaccine.2018.10.033

M3 - Article

AN - SCOPUS:85056621126

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -